Drugs / CABAMIQUINE
CABAMIQUINE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT04250363 | Feb 2020 → Aug 2021 | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | Met primary |
| Phase 1 | NCT03261401 | Sep 2017 → Jun 2019 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05974267 | Nov 2023 → Dec 2024 | Plasmodium falciparum malaria | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT05689047 | Mar 2023 → May 2024 | Plasmodium falciparum malaria | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CABAMIQUINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4091762 ↗ |
| Known as | Cabamiquina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4091762 ↗ |
| Known as | DDD-107498 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4091762 ↗ |
| Known as | DDD498 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4091762 ↗ |
| Known as | M5717 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04250363 ↗ |
| Known as | MMV-121 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4091762 ↗ |
| Action | Inhibit | “M5717 is the first plasmodium translation elongation factor 2 inhibitor to reach clinical development as an antimalarial” PMID 34715032 ↗ Oct 2021 |
| Modality | Small molecule | — CHEMBL4091762 ↗ |
| Route | Oral | “Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast” NCT03261401 ↗ |